

Applicants : Alexander Gad and Dora Lis  
U.S. Serial No.: 09/816,989  
Filed : March 23, 2001  
Page 3

In the Claims

Please amend claims 123, 127, 132-133, 152 and 155-157 in the subject application as set forth below in accordance with 37 C.F.R. §1.121 as amended by 68 Fed. Reg. 38611 (June 30, 2003).

1-122. (Canceled)

123. (currently amended) A method of treating a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids ~~having~~ an the amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7 in an amount effective to treat the ~~mammal~~ human.

124. (previously presented) The method of claim 123 wherein the purified polypeptide consists entirely of L-amino acids.

125-126. (Canceled)

127. (currently amended) The method of claim 123, wherein ~~the~~ purified polypeptide has the amino acid sequence of the consecutive amino acids is set forth in SEQ ID NO: 2.

128-131. (Canceled)

132. (currently amended) The method of claim 123, wherein ~~the~~ purified polypeptide has the amino acid sequence of the consecutive amino acids is set forth in SEQ ID NO: 7.

Applicants : Alexander Gad and Dora Lis  
U.S. Serial No.: 09/816,989  
Filed : March 23, 2001  
Page 4

133. (currently amended) A method of treating a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a pharmaceutical composition comprising a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids having ~~an~~ the amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7, in an amount effective to treat the ~~mammal~~ human and a pharmaceutically acceptable carrier.

134-151. (Canceled)

152. (currently amended) A method of ~~delaying the onset~~ inhibiting the progression of multiple sclerosis in a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids having ~~an~~ the amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7, in an amount effective to ~~delay the onset inhibit the progression~~ of multiple sclerosis in the ~~mammal~~ human.

153. (previously presented) The method of claim 152, wherein, the purified polypeptide consists entirely of L-amino acids.

154. (Canceled)

155. (currently amended) The method of claim 152, wherein ~~the purified polypeptide has~~ the amino acid sequence of the consecutive amino acids is set forth in SEQ ID NO: 2.

156. (currently amended) The method of claim 152, wherein ~~the purified polypeptide has~~ the amino acid sequence of the

Applicants : Alexander Gad and Dora Lis  
U.S. Serial No.: 09/816,989  
Filed : March 23, 2001  
Page 5

consecutive amino acids is set forth in SEQ ID NO: 7.

157. (currently amended) A method of ~~delaying the onset~~  
inhibiting the progression of multiple sclerosis in a ~~mammal~~  
human afflicted with multiple sclerosis comprising  
administering to the ~~mammal~~ human a pharmaceutical composition  
comprising a single purified polypeptide, wherein the purified  
polypeptide comprises consecutive amino acids ~~having an~~ the  
amino acid sequence of which is set forth in any of SEQ ID  
NO:2 or SEQ ID NO:7, in an amount effective to ~~delay the onset~~  
inhibit the progression of multiple sclerosis in the ~~mammal~~  
human and a pharmaceutically acceptable carrier.

158-166. (Canceled)